- Home
- ENGN vs PRQR Comparison
ENGN vs PRQR Comparison
Compare ENGN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- PRQR
- Stock Information
- Founded
- ENGN 1999
- PRQR 2012
- Country
- ENGN Canada
- PRQR Netherlands
- Employees
- ENGN N/A
- PRQR N/A
- Industry
- ENGN
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- PRQR Health Care
- Exchange
- ENGN Nasdaq
- PRQR Nasdaq
- Market Cap
- ENGN 191.1M
- PRQR 179.1M
- IPO Year
- ENGN N/A
- PRQR 2014
- Fundamental
- Price
- ENGN $3.34
- PRQR $2.45
- Analyst Decision
- ENGN Buy
- PRQR Strong Buy
- Analyst Count
- ENGN 7
- PRQR 8
- Target Price
- ENGN $23.29
- PRQR $8.88
- AVG Volume (30 Days)
- ENGN 84.5K
- PRQR 365.1K
- Earning Date
- ENGN 09-09-2025
- PRQR 08-07-2025
- Dividend Yield
- ENGN N/A
- PRQR N/A
- EPS Growth
- ENGN N/A
- PRQR N/A
- EPS
- ENGN N/A
- PRQR N/A
- Revenue
- ENGN N/A
- PRQR $21,212,711.00
- Revenue This Year
- ENGN N/A
- PRQR N/A
- Revenue Next Year
- ENGN N/A
- PRQR N/A
- P/E Ratio
- ENGN N/A
- PRQR N/A
- Revenue Growth
- ENGN N/A
- PRQR 85.91
- 52 Week Low
- ENGN $2.65
- PRQR $1.07
- 52 Week High
- ENGN $11.00
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ENGN 40.69
- PRQR 71.45
- Support Level
- ENGN $2.95
- PRQR $2.10
- Resistance Level
- ENGN $3.98
- PRQR $2.42
- Average True Range (ATR)
- ENGN 0.27
- PRQR 0.14
- MACD
- ENGN 0.02
- PRQR 0.02
- Stochastic Oscillator
- ENGN 34.29
- PRQR 73.17
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.